Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain

Published:2024-01-18 Issue:2 Volume:8 Page:291-302
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Romero Jiménez Rosa María,Herranz Pinto Pedro,Campos Domínguez Minia,Aceituno Mata Susana,Bellmunt Alba,Prades Miriam,Arumi Daniel,Hernández-Martín Irene,Herrera-Lasso Valeria,Llevat Noelia,De Lossada Juste Alfonso,Rebollo Laserna Francisco José^ORCID

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00459-2.pdf

Reference58 articles.

1. Silverberg JI, Feldman SR, Smith Begolka W, Johnson MB, Stanojev C, DiBonaventura M, et al. Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review. J Eur Acad Dermatol Venereol. 2022;36(11):1980–90.

2. Weidinger S, Nosbaum A, Simpson E, Guttman E. Good practice intervention for clinical assessment and diagnosis of atopic dermatitis: findings from the atopic dermatitis quality of care initiative. Dermatol Ther. 2022;35(3): e15259.

3. Sicras-Mainar A, Navarro-Artieda R, Armario-Hita JC. Severe atopic dermatitis in Spain: a real-life observational study. Ther Clin Risk Manag. 2019;15:1393–401.

4. Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760–7.

5. Sicras-Mainar A, Navarro-Artieda R, Carrascosa Carrillo JM. Economic impact of atopic dermatitis in adults: a population-based study (IDEA study). Actas Dermosifiliogr (Engl Ed). 2018;109(1):35–46.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China;Journal of Medical Economics;2024-09-13

2. Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore;PharmacoEconomics - Open;2024-07-13

3. Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate‑to‑severe atopic dermatitis in randomized, double‑blind and placebo‑controlled trials: A systematic review and a meta‑analysis;Biomedical Reports;2024-03-29